The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide
Journal of Bone and Mineral Metabolism · 2026
DOI: 10.1007/s00774-026-01690-7 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Bone and Mineral Metabolism, 2026. Verfasst von Hidehiro Matsumoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Sanzai Hospital, Saito, Japan. Hauptthemen laut MEDLINE: Teriparatide, Bone Density Conservation Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asahi Kasei Pharma Corporation.
Abstract (Originalsprache)
Introduction
Studies launched in Japan on once-weekly teriparatide (1/W-TPTD) and twice-weekly teriparatide (2/W-TPTD) are limited. Therefore, we examined the effects of sequential therapy using anti-resorptive agents after administering 1/W-TPTD and 2/W-TPTD using dual-energy X-ray absorptiometry (DXA) and DXA-based 3D modeling. Materials and methods This was a multicenter retrospective study following a phase 3 clinical trial called the TWICE study. Two-year follow-up data were collected after administering 1/W-TPTD or 2/W-TPTD for 1 year (follow-up after the phase 3 clinical trial).
Results
20 subjects in the group of pre-treatments with 1/W-TPTD followed by sequential administration of bisphosphonate or denosumab (1/W-TPTD [BP/denosumab]), and 22 in the group 2/W-TPTD (BP/denosumab) were included in the analysis of changes in the BMD by post-treatment. In the 1/W-TPTD (BP/denosumab) group, a significant increase in L2–4 BMD was observed. In the 2/W-TPTD (BP/denosumab) group, a significant increase in total hip, neck, and L2–4 BMD values was observed. Analysis by 3D-SHAPER revealed that both the 1/W-TPTD (BP/denosumab) and 2/W-TPTD (BP/denosumab) groups demonstrated significant increases in cortical sBMD and vBMD 2 years after the initiation of post-treatment.
Conclusion
In subjects who received 1/W-TPTD and 2/W-TPTD for about 1 year followed by sequential administration of BP or denosumab, significant improvements in BMD were continuously observed. Furthermore, significant improvements in cortical sBMD and vBMD were also demonstrated by analysis using 3D-SHAPER. Both 1/W-TPTD and 2/W-TPTD were effective in the treatment of osteoporosis by using anti-resorptive agents for sequential administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Sanzai Hospital, Saito, Japan.
- Department of Orthopaedic Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, Japan. m-tsuka@med.uoeh-u.ac.jp.
- Okimoto Clinic, Kure, Japan.
- Department of Orthopaedic Surgery, Ken-Ai Memorial Hospital, Onga, Japan.
- Department of Orthopaedic Surgery, MAZDA Hospital, Fuchu, Japan.
- Takahashi Orthopedics Clinic, Chitose, Japan.
Förderung
- Asahi Kasei Pharma Corporation
Zitieren
APA
Matsumoto, H., Tsukamoto, M., Okimoto, N., Ikeda, S., Tanaka, M., Takahashi, M., Ikejiri, Y., Oha, F., Mizuno, S., Shigenobu, K., Sakai, A., & Takada, J. (2026). The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-026-01690-7
Vancouver
Matsumoto H, Tsukamoto M, Okimoto N, Ikeda S, Tanaka M, Takahashi M, et al. The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide. Journal of Bone and Mineral Metabolism. 2026. doi:10.1007/s00774-026-01690-7
BibTeX
@article{Matsumoto2026,
author = {Matsumoto, Hidehiro and Tsukamoto, Manabu and Okimoto, Nobukazu and Ikeda, Satoshi and Tanaka, Masahiro and Takahashi, Mitsugu and Ikejiri, Yoshiaki and Oha, Fumihiro and Mizuno, Satoshi and Shigenobu, Keiichi and Sakai, Akinori and Takada, Junichi},
title = {The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide},
journal = {Journal of Bone and Mineral Metabolism},
year = {2026},
doi = {10.1007/s00774-026-01690-7}
}
EUVIMED